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Abstract
Background: Children with chronic kidney disease (CKD), requiring dialysis or kidney transplantation, have a
mortality rate of up to 30-fold higher than the general aged-matched population, and severely impaired quality
of life. Symptoms such as fatigue and pain are prevalent and debilitating. Children with CKD are at risk of cognitive
impairment, and poorer educational, vocational, and psychosocial outcomes compared with their well peers, which
have consequences through to adulthood. Treatment regimens for children with CKD are long-term, complex, and
highly intrusive. While many trials have been conducted to improve outcomes in children with CKD, the outcomes
measured and reported are often not relevant to patients and clinicians, and are highly variable. These problems
can diminish the value of trials as a means to improve the lives of children with CKD. The Standardised Outcomes
in Nephrology—Children and Adolescents (SONG-Kids) study aims to develop a core outcome set for trials in
children and adolescents with any stage of CKD that is based on the shared priorities of all stakeholders.
Methods/Design: SONG-Kids involves five phases: a systematic review to identify outcomes (both domains and
measures) that have been reported in randomised controlled trials involving children aged up to 21 years with CKD;
focus groups (using nominal group technique) with adolescent patients and caregivers of paediatric patients (all ages)
to identify outcomes that are relevant and important to patients and their family and the reasons for their choices;
semistructured key informant interviews with health professionals involved in the care of children with CKD to ascertain
their views on establishing core outcomes in paediatric nephrology; an international three-round online Delphi survey
with patients, caregivers, clinicians, researchers, policy-makers, and members from industry to develop consensus on
important outcome domains; and a stakeholder workshop to review and finalise the set of core outcome domains for
trials in children with CKD (including nondialysis-dependent, dialysis, and kidney transplantation).
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Discussion: Establishing a core outcome set to be reported in all trials conducted in children with any stage of
CKD will enhance the relevance, transparency, and impact of research to improve the lives of children and
adolescents with CKD.
Keywords: Core outcome set, Outcomes research, Patient-centred outcomes, Clinical trials, Dialysis, Haemodialysis,
Chronic kidney disease, Paediatrics
Abbreviations: CKD, Chronic Kidney Disease; COMET, Core Outcome Measures Effectiveness Trials;
OMERACT, Outcome Measures Rheumatoid Arthritis Clinical Trials; RCT, Randomised Controlled Trial; SONG-
Kids, Standardised Outcomes in Nephrology-Children and Adolescents; WHO, World Health Organisation
Background
Children with chronic kidney disease (CKD) requiring
dialysis or kidney transplantation have a mortality rate of
up to 30-fold higher than the general population [1]. CKD
also severely impacts the quality of life of affected children
and their caregivers [2–7]. Symptoms such as fatigue, pain,
and oedema, are prevalent and debilitating [8, 9]. Patients
and their caregivers are required to manage a complex and
onerous treatment regimen involving polypharmacy, diet
and fluid restrictions, ongoing clinical appointments, and
for children dependent on renal replacement therapy, a
highly technical and invasive dialysis regimen or kidney
transplantation; all while endeavouring to achieve growth
and developmental milestones [5, 10]. Children with CKD
are at an increased risk of low educational attainment,
cognitive impairment, and worse vocational, psychological,
social, and behavioural outcomes compared with their well
peers [6, 7, 11–14], and these have consequences through
to adulthood [15, 16].
Clinical trials have been conducted in children with
CKD in an effort to improve such unacceptably poor
outcomes. However, the potential of trials to improve
outcomes can only be realised if they address the prob-
lems of relevance to children and families affected by
CKD, and measure the outcomes that are valued by stake-
holders, including children, caregivers and parents, clini-
cians and policy-makers. Unfortunately, empiric studies in
other specialties, have shown that trials commonly use
surrogate endpoints that may not be directly meaningful
to patients and clinicians, and a plethora of different
outcome measures [17]. This can limit the utility of trials
in generating relevant and reliable evidence for decision-
making, which contributes to ‘research waste’ [17].
Surrogate outcomes, such as haematological, bioche-
mical, or imaging outcomes, are commonly used in trials as
they require a smaller sample size, a shorter duration, and
fewer resources to assess the efficacy of treatment; however,
they are largely nonvalidated, heterogeneous, and may not
be relevant to patients. In the Cochrane Central Register of
Controlled Trials [18], trials in children with CKD appear
to be largely focussed on growth, anaemia, nutrition, im-
munosuppression, and dialysis-related interventions and
mostly report surrogate outcomes such as parathyroid
hormone, serum calcium, and haemoglobin status, and
kidney function [19–25]. Systematic reviews have shown
that patient-relevant outcomes, such as mortality and
cardiovascular disease, are infrequently included [25, 26]
and quality of life outcomes are scarcely reported. Studies
that have directly elicited perspectives from children with
CKD have identified that anxiety, school attendance and
achievement, social participation, hospitalisation, and
fatigue, are important and relevant to them [7, 10, 27–29],
yet these are not typically measured or reported in trials.
The uncertainty about the relevance of trial outcomes
to patients, caregivers, and clinicians has important
implications for children with CKD, as treatment can be
highly intrusive and onerous, with profound impacts on
health and lifestyle. Also, shared decision-making can be
particularly challenging in this vulnerable population
given their younger age and higher risk of neurocogni-
tive dysfunction [12, 13, 30]. These challenges highlight
the need for systematic, collaborative and concerted
efforts to engage children with CKD and their families in
explicitly identifying the outcomes that they regard as
important for research, and to understand the reasons for
their preferences.
Systematic problems are also evident in how outcomes
are measured and reported. Substantial variability is usu-
ally found, making judgements about the relative efficacy
of interventions very difficult, and this contributes to inef-
ficiencies in research. For example, in a Cochrane review
of recombinant human growth hormone for children in
any stage of CKD involving 16 trials (n = 809 children), 7
(44 %) trials reported change in height standard deviation
score (SDS), 6 (38 %) reported height velocity, 3 (17 %)
reported height SDS, 3 (17 %) reported height velocity
SDS, and 2 (11 %) reported change in height velocity.
Many initiatives have been established worldwide to
develop core outcome sets to improve the relevance and
consistency of outcome measurement and selection. Core
outcomes are defined as the minimum set of outcomes
that should be measured and reported in clinical trials of a
specific condition, though may also be used for other
types of research and quality improvement activities [31].
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Standard sets of outcomes have also been touted as ‘a prac-
tical and decisive step in accelerating value improvement in
health care’ [32]. The Outcome Measures in Rheumatology
(OMERACT) commenced in 1992 and set foundational
work in the development of core outcomes, which has
led to more complete reporting of relevant outcomes in
rheumatology trials. The Core Outcome Measures in
Effectiveness Trials (COMET) was then formed to provide
a central resource and portal for the development and
dissemination of core outcome sets [31]. Consensus-based
core outcome sets for paediatric conditions are sparse, but
have been conducted in the areas of otitis media [33, 34],
asthma [35], neurodisability [36], autism [37], and cerebral
palsy [38]. Recently, there have been major efforts to vali-
date patient-reported outcome measures in children with
CKD to assess disease severity and activity [39]; however,
the outcome domains that are explicitly prioritised by
patients and clinicians to be important remain to be iden-
tified. No core outcome set exists in paediatric nephrology.
The Standardised Outcomes in Nephrology—Children
and Adolescents (SONG-Kids) study aims to establish a
core outcome set for trials in children and adolescents
aged up to 21 years of age across all stages of CKD
(including nondialysis-dependent, dialysis, kidney trans-
plantation), which may also be used in other research
contexts. The upper age limit to define the paediatric
population varies internationally and is up to 21 years in
the United States [40]. The SONG-Kids Steering Group
was convened in February 2016, and is comprised of 14
paediatric nephrologists from seven countries who have
experience in clinical trials, outcomes research, and imple-
mentation. The specific objectives of SONG-Kids are to:
(1) describe the scope and consistency of outcomes used
in haemodialysis trials, (2) identify outcomes that are
important to children with CKD and their caregivers and
elucidate the reasons for their choices, (3) ascertain health
professional perspectives on core outcomes in paediatric
CKD, (4) develop a core outcome domain set based
on consensus across all stakeholder groups including
patients/caregivers and health professionals, and (5) estab-
lish a core outcome domain set for trials in children with
CKD.
Methods/design
The SONG-Kids methodology is adapted from the pro-
cesses used in the SONG initiative [41] and the World
Health Organisation (WHO)-endorsed OMERACT frame-
work [42] as these have been recognised as a valid approach
for establishing core outcomes. SONG-Kids involves five
phases: systematic review, focus groups with nominal group
technique conducted with adolescents with CKD and their
parents (or other caregivers), stakeholder interviews, an
online Delphi survey, and a consensus workshop (Fig. 1).
Phase 1: systematic review of outcome domains and
outcome measures reported in trials of interventions for
children with chronic kidney disease
We will conduct a systematic review to identify and
compare outcome domains and measures reported in
randomised controlled trials (RCTs) of interventions for
children in any stage of CKD.
Search strategy
We will search the Cochrane Central Register of Controlled
Trials (CENTRAL) to find all RCTs involving children with
any CKD diagnosis and treatment stage of CKD (CKD
stages 1–5 (nondialysis-dependent), 5D (on haemodialysis
or peritoneal dialysis), and 5 T (kidney transplantation)).
No date or language restrictions will be applied.
Types of studies
We will include all RCTs published in peer-reviewed
journals. Conference reports and abstracts will not be in-
cluded as we are assessing the outcome reported, not
the results associated with those outcomes. Given the
space constraints of abstracts and conference reports,
they are not a reliable source of all of the outcomes mea-
sured and reported in trials.
Types of interventions
Any intervention for children with CKD (CKD stages 1–5
(nondialysis-dependent), CKD stage 5D (haemodialysis or
peritoneal dialysis), or CKD stage 5 T (kidney transplan-
tation)) will be eligible. Types of interventions can include,
but will not be limited to, pharmacological, surgical, psy-
chosocial, and health service interventions.
Types of participants
Children aged 21 years or below with CKD. A trial will be
eligible if it can be determined that more than 50 % of
participants across all arms are aged 21 years or below.
Exclusion criteria
RCTs that only include patients aged above 21 years, or
include children with chronic conditions in which the data
from the CKD population are not reported separately, will
be excluded.
Eligibility of studies
Two reviewers will independently assess all records ob-
tained from the searches. Full texts of all potentially
relevant systematic reviews and RCTs will be assessed inde-
pendently by the two reviewers and any disagreement on
the eligibility of included studies will be resolved through
consultation with a third reviewer.
Tong et al. Trials  (2016) 17:401 Page 3 of 11
Data extraction
The primary reviewer will extract from all included trials
the following: first author, date of publication, country/ies
in which the trial was conducted, sample size, participant
characteristics (age, gender), trial duration, treatment
stage of CKD (nondialysis-dependent CKD, haemodialysis,
peritoneal dialysis, living donor and deceased donor
kidney transplantation), name and type of intervention
(e.g. pharmacological, surgical, psychosocial, lifestyle), and
all outcomes as reported in the trial (definitions, specific
measures, thresholds, time points or time frames for
measurement, change in level or percentage, scores). At
least three reviewers (including two paediatric nephro-
logists) will cross-check the data extraction.
Data analysis and presentation
The data will be entered into Microsoft Excel to assist
with data management. Two reviewers will group similar
outcomes into outcome domains, and the outcome do-
mains will then be classified as surrogate (biochemical or
physiological outcomes that may or may not be validated),
clinical (medical outcome based on clinician assessment),
or patient-reported outcomes (outcomes reported by the
patients usually relating to quality of life or symptoms).
These classifications will be reviewed and discussed by the
SONG-Kids Steering Group via email and teleconference.
Any disagreements will be resolved by consensus among
the Steering Group. We will ascertain the frequency with
which each outcome domain was reported across trials.
For each outcome domain, we will count the number of
different outcomes (including measures) and the number
of trials that assessed each specific outcome. We will use
the software package R (version 3.2.3) to perform all sta-
tistical analyses.
Phase 2: focus groups with modified nominal group
technique
Children and parents of children with CKD will be asked
to identify and prioritise outcomes that they consider
are relevant and important to measure in trials, and to
discuss the reasons for their choices. The nominal group
technique is a transparent and systematic process for
achieving consensus within a structured group discussion,
and has been used to define research and health service
priorities [43–47]. This technique is useful for generating
a prioritised set of ideas and minimises individual partici-
pants from dominating the discussion, facilitates equitable
and active contribution, and mitigates direct criticism and
rejection among participants [47]. Previous studies have
demonstrated the feasibility of focus groups with prio-
ritisation exercises in children [48–50].
Participants and recruitment
Children aged 12 to 21 years with CKD (not on dialysis
(CKD stages 1–5)), on haemodialysis or peritoneal dialysis
(CKD stage 5D), or who have received a kidney trans-
plantation (CKD stage 5 T)) and parents/caregivers of
children aged 21 years or below with CKD are eligible to
participate. Recruitment will be mostly focussed on chil-
dren receiving treatment for CKD who are likely to pro-
gress to end-stage kidney disease, and who are able to
discuss their experiences and perspectives of CKD in the
English language. Most children with early stage CKD are
asymptomatic and may not be receiving treatment, thus
we will focus on recruiting children with more advanced
CKD or those who are receiving renal replacement the-
rapy in the form of dialysis or kidney transplantation. All
causes and types of CKD (e.g. birth defects, hereditary dis-
eases, hereditary nephritis, infection, nephrotic syndrome,
systemic diseases (lupus nephritis, diabetes)) will be
included.
We will convene a total minimum of 16 focus groups
(with ten participants per group) based on the following
population:
1. Children aged 12 to 21 years not on renal
replacement therapy (four groups)
2. Children aged 12 to 21 years on renal replacement
therapy in the form of dialysis of kidney
transplantation (four groups)
3. Parents of children (aged 0 to 21 years) not on renal
placement therapy (four groups), and
Fig. 1 SONG-Kids process
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4. Parents of children (aged 0 to 21 years) on renal
replacement therapy (four groups)
The groups will be convened until data saturation, i.e.
when no new outcomes or perspectives relevant to the
study are being raised in subsequent groups. Depending
on the patient population at each participating site, we will
convene the child focus groups by treatment and age
group (12–16 years and 17–21 years) if feasible.
Participants will be recruited from the participating cen-
tres in Australia (The Children’s Hospital at Westmead,
Royal Children’s Hospital, Royal Children’s and Mater
Children’s Hospital), Canada (Alberta Children’s Hospital,
BC Children’s Hospital), and the United States (Baylor
College of Medicine). A purposive sampling will be ap-
plied to include a broad range of demographic (age,
gender, socioeconomic status, educational level, ethnicity)
and clinical (patient stage of CKD including treatment
modality, cause or diagnosis of CKD, comorbidities) char-
acteristics. Informed consent will be obtained from all
participants aged 18 years and over. Participants under 18
years of age (or otherwise depending on local regulations)
will be asked to provide written consent or assent; and
consent will be sought from their adult legal guardian
in accordance with ethical requirements at each partici-
pating site.
Data collection
The focus groups will be up to 2 hours in duration and
convened in a meeting room external to the hospital
setting to encourage open discussion in a neutral envi-
ronment. The questions will be adapted from focus
group guides used to elicit perspectives on outcomes for
research among adult patients who are on haemodialysis
or have received a kidney transplantation [44, 46], and
discussed among the Steering Group. A facilitator with
training and experience in nominal group technique will
moderate the discussion. A note-taker will record notes
on the group dynamics, disposition and interaction
among the participants. Separate focus-group-run sheets
and timings will be developed for parents and children;
however, both sets of focus groups’ questions will cover
the three stages described in the following section:
1. Welcome and introduction, including an explanation
about research and outcomes (15 min)
2. Focus group discussion (20 min): participants will be
asked to talk generally about their experiences and
perspectives of CKD, aspects of CKD or treatment
that are most important to participants, the
perceived benefit, harms and challenges of different
treatment/interventions
3. Nominal group technique (50 min): participants will
be asked to write one or two outcomes on a notepad
that they think are important for research. The
facilitator (AT/CSH) will ask participants in turn to
read out their suggestions, and will write (draw)
them on a board. Each outcome will be discussed
and defined. Other outcomes identified from phase
1 (systematic review) will be added to the list. A list
will be printed for participants. Participants will be
asked to rank the outcomes (at least the top ten) in
order of importance from 1 (most important) to X
(least important).
Participants will be given the opportunity to discuss any
similarities and differences in their opinion. All focus
groups will be audio-recorded and transcribed verbatim.
The outcomes from each group will be reviewed and
discussed among the investigator team, which include
paediatric nephrologists.
Data analysis
Quantitative rating/ranking: we will extract the top ten
ranked outcomes for each participant. The highest ranked
outcome for each participant will be reverse-coded and
assigned a value of 10, and the least important a value of
1. Outcomes that were excluded from the top ten or not
ranked will be given a value of zero. The individual rank
scores for all participants across all groups will be used to
determine the mean rank score for the top ten most
important outcomes from the full set of outcomes. We
will also assess the proportion of participants who ranked
a specific outcome in the top ten most important out-
comes. This will be used to generate a list of outcomes
ordered by the mean priority score. We will also calculate
the mean rank scores separately for patients and parents/
caregivers with the statistical significance of the differences
assessed on the basis of a t test, considered significant at
p < 0.05. A covariate adjustment for group composition
will also be conducted. The analysis will be conducted
using the statistical package SPSS.
Qualitative analysis: the transcripts will be imported into
HyperRESEARCH (ResearchWare Inc. www.researchware.
com, version 3.7.2) software for qualitative data analysis.
Using thematic analysis, we will review the transcripts line-
by-line and inductively code for concepts and themes that
emerge from the data that provide the reasons underpin-
ning the participants’ ranking choices. Similar concepts will
be grouped into themes and subthemes. The preliminary
findings will be discussed among the research team to
ensure that the analytical themes capture the diversity and
depth of the data.
Phase 3: semistructured key informant interviews
Semistructured key informant interviews will be con-
ducted with health professionals to ascertain a range and
depth of their individual perspectives on establishing core
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outcomes for research in children with CKD. We will
follow the Consolidated Criteria for Reporting Qualitative
Health Research (COREQ) [51].
Participants and recruitment
Health professionals who have experience and expertise in
paediatric CKD will be eligible to participate in an inter-
view. Health professionals will include paediatric nephro-
logists, surgeons, nurses, allied health professionals (e.g.
psychologists, social workers, dieticians), researchers, and
policy-makers. A minimum of 50 participants will be
recruited across all regions worldwide and identified from
established networks of the Steering Group and Investi-
gators. Participants will be purposively sampled to ensure
that a range of demographic and professional roles and
experiences are obtained. We will recruit until data satu-
ration, which we will define as when no new concepts
or outcomes are being identified in three consecutive
interviews. We will obtain informed consent from all
participants.
Data collection
The interview guide will incorporate findings from phases
1 and 2. The interviews will be conducted face-to-face;
however, Skype or telephone interviews will be an option
if preferred by the participants or when an in-person
interview cannot be feasibly arranged. Participants will be
prompted to discuss their perspectives on: (1) their expe-
riences in providing care for children with CKD and
aspects of treatment that are important and challenging,
(2) outcomes currently measured and reported in paedia-
tric nephrology trials and the implications on practice and
policy, (3) outcomes they believe are important and rele-
vant for trials and the reasons why, and (4) perspectives
on the development and implementation of core out-
comes for trials in children with CKD. The interview will
take approximately 40 min, and will be audio-recorded
and transcribed.
Data analysis
From the transcripts, we will extract all outcomes iden-
tified by participants (to inform the Delphi survey in phase
4). We will use thematic analysis, as described in phase 2,
to identify the themes that reflect their perspectives,
beliefs, priorities, and values about core outcomes for
research in children with CKD. To ensure that the full
range and depth of the data are included in the analysis, at
least two investigators (AT, CSH), will be involved in
coding the data analysis to develop descriptive and analy-
tical themes (investigator triangulation). The preliminary
results will also be reviewed by the interview participants
(member checking) and the SONG-Kids Steering Group.
Phase 4: international online Delphi consensus survey
An international online SONG-Kids Delphi survey will be
conducted to generate consensus on the outcome domains
that are most important to all stakeholder groups. The
Delphi survey has been used as a reliable approach for
gaining consensus on core outcome sets across a range of
health conditions [34, 52–57]. This technique involves two
or three rounds of surveys completed anonymously by
participants who have knowledge, experience, or expertise
on the topic [47, 58]; this allows participants to contribute
their perspectives and provide feedback on the group
results, and allows respondents to revise their opinions after
reflecting on the group responses [59]. This process facili-
tates equitable contribution from all members of the Delphi
panel as participants are protected from direct confron-
tation so they are able to communicate their individual
perspectives. We will use a reporting checklist for Delphi
studies on developed core outcomes, developed by Sinha et
al. (2011), which addresses the size and composition of the
Delphi panel, methodology and process, and results of the
Delphi survey [58]. However, the approach will be adapted
for the child version of the Delphi survey for age-
appropriateness. The Delphi survey has been used in chil-
dren with chronic conditions [27, 34, 35, 38].
Participants and recruitment
There is no standard sample size calculation or recom-
mendation for a Delphi study [60]. Most Delphi surveys
used to develop core outcomes have included fewer than
200 respondents, though a Delphi survey used to develop
core outcomes for trials involving adults on haemodialysis
(SONG-HD) and kidney transplantation (SONG-Tx) in-
cluded approximately 1000 participants.
Our minimum target sample size will be 500 respondents
with at least 100 children aged 8–21 years with CKD (not
on dialysis (CKD stages 1–5), on haemodialysis or perito-
neal dialysis (CKD stage 5D), or who have received a kidney
transplantation (CKD stage 5 T)); 150 caregivers of children
with CKD, and 250 health professionals. This is based
on the estimated patient population at recruiting hospitals,
and members of health professional societies in paediatric
nephrology. We will aim to recruit physicians (paediatric
nephrologists, surgeons, psychiatrists (minimum n = 170);
nursing and allied health professionals (pharmacists, die-
titians, psychologists, social workers) (n = 50); and policy-
makers, researchers, and representatives from industry
(n = 30); who have experience, expertise, or interest in
outcomes in children with CKD.
We will seek to obtain a broad range of demographics,
clinical characteristics (patients), and professional expe-
riences and roles (health professionals); and will also
use snowballing strategies (where participants can nomi-
nate or extend an invitation to other relevant stake-
holder members to participate). Patients/caregivers will be
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primarily recruited via the investigator’s hospital/univer-
sity sites, which are in Australia, Canada, Europe, the
United Kingdom, the United States, and Singapore, and
patient/consumer organisations, and the SONG Initiative
database. Health professionals will be invited via profes-
sional paediatric nephrology societies and existing networks
of the SONG-Kids Steering Group and Investigators.
Data collection
Generating the list of outcomes The Delphi survey will
include outcome domains from the systematic review of
outcomes reported in RCTs (phase 1) and outcomes iden-
tified in the nominal group technique study (phase 2).
All outcomes will include a plain language definition
(Flesch-Kincaid Index of grade 5 readability (age 10 years)).
The child version for patients aged 8 to 18 years will
include a picture to illustrate the outcome and an expla-
nation in child-friendly terms. An audio button will also be
embedded in each outcome so participants can hear the
outcome read aloud. The adult version for patients aged 18
to 21 years, caregivers, and health professionals will also
include a more detailed definition if appropriate. The
survey will be reviewed by the SONG Executive and
SONG-Kids Steering Group and Investigators, which
includes members who are children with CKD and par-
ents of children with CKD, and will be piloted with at least
five patients with CKD and five parents/caregivers.
Survey administration All participants will register their
name and email address via www.songinitiative.org after
receiving an information and consent form from recruit-
ing sites. Participants recruited via collegial networks or
social media will receive an information form upon regis-
tration. A statement of informed consent will be provided
at the beginning of the survey. For children aged under 18
years, parents will also be required to provide consent for
their child to participate. The surveys will be administered
using the online survey platform, LimeSurvey, which will
be optimised for viewing using both desktop and smart-
phone. Each participant will be given a unique identifier
so we can monitor and link their responses anonymously.
At least three reminders will be sent to participants during
the Delphi survey rounds in an attempt to retain at least a
70 % response rate across all three rounds. Participants
who complete all three rounds will receive a copy of the
preliminary results to provide feedback and comment.
Delphi survey round 1 Participants will be presented
with the question: ‘how important is this outcome for
research in children with CKD?’ and asked to rate the
importance of each outcome domain (approximately 30)
using the GRADE 9-point Likert scale [61]. The visual scale
used for each outcome will indicate ratings 1 to 3 as of
‘limited importance’, 4 to 6 as ‘important, but not critical’,
and 7 to 9 as of ‘critical importance’. An option ‘I don’t
know’ will also be provided.
For each outcome, a free-text box will be provided so
participants can provide optional comments. To mini-
mise ordering bias, the order of outcomes shown will be
randomised. Participants can suggest new outcomes. All
new outcomes that are suggested by more than 10 % of
participants that do not overlap or duplicate outcomes
will be recoded by at least two investigators (NE, CSH)
and reviewed by the SONG-Kids Steering Group, then
carried through to round 2.
We will review the distribution of scores across all
outcomes. Any outcome with a median and mean of more
than 7 (with 70 % or more participants in both patient/
caregiver and health professionals rating the outcome 7–9;
based on the OMERACT criteria for "consensus in") will be
carried through to round 2. Any outcomes excluded in
subsequent rounds will be listed in the research agenda
(Fig. 2).
Delphi survey round 2 In round 2, participants will be
presented with a column graph of the distribution of scores
for each outcome for the following groups: (1) patients/
family members/donors, (2) health professionals, and (3) all
participants (with scores weighted evenly between groups).
An explanation of how to read the graph will be provided
to ensure that participants can understand and interpret
the graph clearly. For the child version, an animation to
explain how to understand the group results will be shown.
They will also see comments from round 1 by patients/
family members/donors and health professionals. The
comments may be edited for clarity and readability. Their
own response from the previous round will be highlighted
in the rating scale. Participants will rerate each outcome
and any additional outcomes identified in round 1 using
the same 9-point Likert scale. An optional free-text box will
be provided for participants to state reasons for their rating,
or to provide feedback or responses to the participant
comments.
All outcomes with a median and mean of more than 7
(with 70 % or more participants in both patients/care-
givers and health professionals rating the outcome 7–9)
will be included in round 3.
Delphi survey round 3 Participants will see the distribu-
tion of scores for each outcome for all participants and by
stakeholder groups, and comments from round 2 in the
same format as the previous round. Participants will see
their own score from round 2 highlighted in the rating
scale and rerate all outcomes. A free-text box will be pro-
vided for participants to make any additional comments.
After the rating questions, participants will be asked to
complete a forced ranking exercise. They will be presented
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with a list of all outcomes to arrange into a list in order of
importance from most important to least important.
Data analysis
For all three rounds, we will summarise the distribution of
scores and calculate the mean, median and proportion for
ratings and rankings of each outcome. The OMERACT
prespecified definition of ‘consensus’ for outcomes to be
included in the core set states that the outcome must have
at least 70 % of participants scoring 7 to 9, and fewer than
15 % of participants scoring as 1 to 3 [41]. Based on pre-
vious initiatives and feasibility, three to five outcomes will
be included in the core outcome set. If more than five
outcomes will meet the OMERACT threshold for inclu-
sion, the preliminary core outcome domains will also be
determined based on means, medians, and proportions in
round 3, which will be validated against the OMERACT
cut-offs based on proportions. Since the thresholds may
need to be defined post hoc, the rationale and threshold
for inclusion will be detailed in a plain language report for
transparency. This will also be discussed in the consensus
workshop outlined in the next section.
Phase 4: Consensus workshop
A consensus workshop will be convened with stakeholders
to review the results from phases 1 to 3 and discuss the
identification of core outcomes (including the potential
set of core outcomes). The workshop will be held in
conjunction with an international paediatric nephrology
conference. SONG-Kids Steering Group members will
chair and facilitate the session. Approximately 60 dele-
gates; including at least 20 patients/family members will
be invited to attend the workshop. Health professionals
with a range of clinical experience in paediatric nephro-
logy (nephrologists, surgeons, nursing and allied health
professionals), expertise in research (epidemiology, clinical
trials in children with CKD, registries, quality improve-
ment), and leadership or advisory roles in major research
Phase 1 | Systematic review
Phase 4 | Delphi Survey




1. Consider outcomes from systematic review
2. Consider patient-prioritised outcomes from 
nominal group technique (Phase 2)
3. Develop child and adult version using the   
same outcomes
4. Review by SONG-Kids Steering Group
5. Pilot
• Identify outcomes in RCTs involving children 
with CKD
1. Participants rate the importance of each
outcome on a likert scale from 1 to 9
(based on GRADE)
2. Provide comments (optional)
3. Suggest new outcomes
ROUND 2
Exclude outcomes
• Median, mean < 7 for 
both groups
• >70% each group rating 
below 7)
1. Participants see own score
2. See comments from all participants
(anonymous)
3. See distribution of scores by groups
4. Re-rate outcomes from 1 to 9
5. Provide a comments (optional)
Include outcomes
• Suggested by >10 % of 
participants
Exclude outcomes
• Median, mean < 7 for 
both groups
• >70% each group rating 
below 7)ROUND 3
1. Participantsseeown score
2. See comments from all participants
(anonymous)
3. See distribution of scores by groups
4. Re-rate outcomes from 1 to 9
5. Forced ranking of all outcomes
6. Provide comments (optional)
Potential core
outcome domains
• Top 3-5 outcomes based on means, 
medians, proportions
• Review potential core outcome set
• Discuss strategies for implementation
Finalise core outcome domains
• Integrate workshop discussion
• Elicit public/stakeholder comments
• Finalise core outcomes
Phase 2 | Nominal group • Patients (aged 12-21 years) and caregivers 
identify and priorities outcomes, and 
discuss reasons for their choices (minimum 
16 groups)
Phase 3 | Stakeholder interviews • Interviews with health professionals 
involved in the care of children with CKD
Fig. 2 Conceptual schema of core outcomes
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and policy organisations (including regulators), and indus-
try will be invited to attend.
Prior to the workshop, we will send participants a copy
of the results from phases 1 to 3. The child version will
include a link to an online animation to explain the
results, and all materials will be developed to meet the
Flesch-Kincaid Index of grade 5 readability (age 10 years).
Participants will be asked to reflect on the results to date
so they may be better prepared to contribute their feed-
back during the workshop. The workshop will include
three sessions:
Session 1: Introduction
We will provide a brief introduction to the SONG-Kids
initiative and present the details of the SONG-Kids
process and results from phases 1 to 3, and the
preliminary core outcome set and proposed
threshold for inclusion.
Session 2: Breakout groups
Participants will be allocated to five breakout groups
with up to 12 participants in each group (including a
facilitator and a cofacilitator). Mixed stakeholder
groups with at least two family members will be
convened to encourage a richer exchange of ideas,
explanations of similar or different opinions, and
breadth of discussion. Patients aged 12 to 18 years will
be allocated to a separate group.
A trained facilitator will ask participants to discuss the
identification and implementation of core outcomes,
and ensure cooperative, respectful, and inclusive
discussion. All facilitators will attend a briefing session
and will be provided with a question guide.
Session 3: Plenary discussion
The groups will reconvene to engage in a broader
discussion moderated by the workshop chair. One
person from each breakout group will present a brief
summary of their discussion. The wider group will be
invited to give their opinions and reflections on the
issues raised by other groups. The moderator will
summarise key similarities and differences in the points
raised across groups.
The moderator may ask participants to formally endorse
the proposed core outcomes’ set.
Finalisation of core outcome domains
The SONG-Kids process (phases 1 to 4) and proposed
outcomes will be published in a plain language report for
circulation to the participants in the Delphi (phase 3) and
consensus workshop (phase 4), circulated to stakeholder
groups and made available on the website for 3 weeks to
obtain public comment. A child version will also be deve-
loped. All feedback will be reviewed by the SONG-Kids
Steering Group and SONG Executive Committee to fina-
lise the SONG-Kids core outcome set.
Discussion
The SONG-Kids project uses a systematic and transparent
process that will engage children, caregivers, clinicians,
policy-makers, and researchers to develop a prioritised set
of core outcome domains for trials in children with CKD
based on consensus. The core outcomes will help to
ensure that the outcomes of real importance to children,
their families, and health care professionals involved in
their care, are the focus of attention—not necessarily that
which is easy to measure, or has been measured and
reported historically. The core outcomes may also be
considered for other types of research including obser-
vational studies and quality improvement projects. Once
the core outcome domains are finalised we will identify,
and if necessary, develop core outcome measures that are
valid, discriminative and feasible.
We will consult with key stakeholders to ensure that the
core outcomes will be disseminated and translated via
international and national policy and research organisa-
tions. Complete and consistent reporting of outcomes that
are highly relevant to patients, practitioners, policy-makers,
and researchers will improve the relevance and value of
research for informing decision-making in the care of
children with CKD. Ultimately, this may also direct the
research agenda towards improving outcomes that are
important to patients, providers, and policy-makers.
Study status
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